Buspirone
Also known as: Buspar, buspirone hydrochloride
Buspirone is an anti-anxiety medication that works differently from benzodiazepines — it's not sedating, not habit-forming, and doesn't cause the same dependence issues as Xanax or Valium. The tradeoff is that it takes 2–4 weeks to work rather than working immediately. It's often used for generalized anxiety disorder, sometimes alongside an SSRI, and is considered a safer long-term option for people who need ongoing anxiety management without the risks of benzodiazepine dependence.
What it is
Buspirone is an azapirone anxiolytic — a class of anti-anxiety drugs distinct from benzodiazepines, barbiturates, and other sedative-hypnotics. It acts primarily as a partial agonist at serotonin 5-HT1A receptors and as a dopamine D2 receptor antagonist. Unlike benzodiazepines, buspirone does not enhance GABA activity, does not cause sedation, does not impair psychomotor performance, and does not produce physical dependence or a clinically significant withdrawal syndrome.1
The delayed onset of buspirone's anxiolytic effects (2–4 weeks for full effect) is the primary practical limitation. Patients accustomed to the immediate relief of benzodiazepines often perceive buspirone as ineffective during the first weeks of treatment.
FDA-approved indications
Management of anxiety disorders or short-term relief of symptoms of anxiety.1
Typical dosing
Starting dose: 7.5 mg twice daily. Increase by 5 mg per day every 2–3 days as needed. Usual effective dose: 15–30 mg per day in divided doses. Maximum recommended dose: 60 mg per day.1
Route of administration
Oral tablets.
Storage & handling
Store at controlled room temperature, away from heat and moisture.1
Common considerations
Key considerations from the FDA label:1
- Serotonin syndrome risk: Buspirone has serotonergic activity and when combined with SSRIs, SNRIs, triptans, MAOIs, or other serotonergic agents, may increase the risk of serotonin syndrome. The sertraline FDA label specifically lists buspirone as a drug that increases serotonin syndrome risk when combined.
- MAOIs: Do not use buspirone within 14 days of MAOI use — risk of hypertensive crisis and serotonin syndrome.
- CYP3A4 interactions: Buspirone is extensively metabolized by CYP3A4. Erythromycin, itraconazole, nefazodone, and grapefruit juice can significantly increase buspirone plasma levels. Rifampin substantially reduces buspirone levels.
- No cross-tolerance with benzodiazepines: Buspirone will not prevent benzodiazepine withdrawal symptoms and is not a substitute for benzodiazepines in patients who have been taking them regularly.
- Driving and machinery: Less sedating than benzodiazepines, but some CNS effects may occur, particularly early in treatment.
- Pregnancy: Insufficient human data; animal studies showed adverse effects at high doses.
References
The information on this page is provided for general educational purposes only. It is not medical advice and is not a substitute for consultation with a qualified healthcare provider. Individual needs, contraindications, and responses to supplementation vary, and decisions about starting, stopping, or modifying any supplement or medication should be made in consultation with a physician, pharmacist, or other appropriate professional. References are provided to authoritative sources; STACK Tracker does not endorse any specific product or brand.